GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » Asset Turnover

Lexaria Bioscience (Lexaria Bioscience) Asset Turnover : 0.03 (As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Lexaria Bioscience's Revenue for the three months ended in Feb. 2024 was $0.15 Mil. Lexaria Bioscience's Total Assets for the quarter that ended in Feb. 2024 was $4.99 Mil. Therefore, Lexaria Bioscience's Asset Turnover for the quarter that ended in Feb. 2024 was 0.03.

Asset Turnover is linked to ROE % through Du Pont Formula. Lexaria Bioscience's annualized ROE % for the quarter that ended in Feb. 2024 was -50.67%. It is also linked to ROA % through Du Pont Formula. Lexaria Bioscience's annualized ROA % for the quarter that ended in Feb. 2024 was -52.11%.


Lexaria Bioscience Asset Turnover Historical Data

The historical data trend for Lexaria Bioscience's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience Asset Turnover Chart

Lexaria Bioscience Annual Data
Trend Oct13 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.14 0.09 0.02 0.04

Lexaria Bioscience Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.02 - 0.05 0.03

Competitive Comparison of Lexaria Bioscience's Asset Turnover

For the Biotechnology subindustry, Lexaria Bioscience's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Asset Turnover falls into.



Lexaria Bioscience Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Lexaria Bioscience's Asset Turnover for the fiscal year that ended in Aug. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Aug. 2023 )/( (Total Assets (A: Aug. 2022 )+Total Assets (A: Aug. 2023 ))/ count )
=0.226/( (7.834+3.084)/ 2 )
=0.226/5.459
=0.04

Lexaria Bioscience's Asset Turnover for the quarter that ended in Feb. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=0.145/( (3.627+6.352)/ 2 )
=0.145/4.9895
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Lexaria Bioscience  (NAS:LEXX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Lexaria Bioscience's annulized ROE % for the quarter that ended in Feb. 2024 is

ROE %**(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=-2.6/5.1315
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.6 / 0.58)*(0.58 / 4.9895)*(4.9895/ 5.1315)
=Net Margin %*Asset Turnover*Equity Multiplier
=-448.28 %*0.1162*0.9723
=ROA %*Equity Multiplier
=-52.11 %*0.9723
=-50.67 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Lexaria Bioscience's annulized ROA % for the quarter that ended in Feb. 2024 is

ROA %(Q: Feb. 2024 )
=Net Income/Total Assets
=-2.6/4.9895
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-2.6 / 0.58)*(0.58 / 4.9895)
=Net Margin %*Asset Turnover
=-448.28 %*0.1162
=-52.11 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Lexaria Bioscience Asset Turnover Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexaria Bioscience (Lexaria Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Executives
Catherine C. Turkel director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Gregory Downey officer: Chief Financial Officer 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka director, 10 percent owner, officer: CEO 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Vanessa Carle officer: Secretary 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Reese Albert L Jr director
Brian W. Quigley director 100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie director 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger officer: CFO 8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty director, 10 percent owner 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar director, officer: CFO 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter director 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford director 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke officer: Sr. VP, Business Development 38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini director, 10 percent owner 11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan director, officer: Vice President - Corp Develop SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6